Fortress Biotech Files SC 13D/A Amendment

TL;DR

Fortress Biotech filed an update on its Checkpoint Therapeutics stake. Watch for more details.

AI Summary

Fortress Biotech, Inc. filed an amendment (No. 7) to its Schedule 13D on May 17, 2024, regarding its beneficial ownership of Checkpoint Therapeutics, Inc. common stock. The filing indicates a change in the reporting person's holdings, though specific new percentages or dollar amounts are not detailed in this excerpt. Fortress Biotech, Inc. is located in Bay Harbor Islands, FL.

Why It Matters

This filing updates the market on Fortress Biotech's stake in Checkpoint Therapeutics, potentially signaling changes in their strategic relationship or investment. Investors will monitor this for insights into Fortress's confidence in Checkpoint's prospects.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant stake changes or activist intentions, which can introduce volatility and uncertainty for the subject company and its investors.

Key Players & Entities

• Fortress Biotech, Inc. (company) — Reporting Person
• Checkpoint Therapeutics, Inc. (company) — Issuer
• Lindsay A. Rosenwald, M.D. (person) — Contact Person for Fortress Biotech

FAQ

Key Financial Figures

• $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.00
• $1.29 — rrants, which have an exercise price of $1.29 per share, are exercisable until July 1

Filing Documents

• tm2414876-1_sc13da.htm (SC 13D/A) — 48KB
• 0001104659-24-063092.txt ( ) — 50KB

and the Warrants in Footnote 1 above

Item 3 and the Warrants in Footnote 1 above. Item 7. Materials to be Filed as Exhibits. Exhibit 7.01 Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., dated March 3, 2015, incorporated by reference to Exhibit 3.1 to the Form 10-12G filed by the Issuer with the SEC on July 11, 2016 (File No. 000-55506).* Exhibit 7.02 Amendment to the Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., dated June 14, 2018, incorporated by reference to Exhibit 10.1 to the Form 10-Q filed by the Issuer with the SEC on August 7, 2018 (File No. 001-38128).* Exhibit 7.03 Form of Amended and Restated Common Stock Warrant issued by Reporting Person to Dr. Rosenwald and Mr. Weiss for Issuer common stock, incorporated by reference to Exhibit 7.01 to the Schedule 13D filed by the Reporting Person with the SEC on May 26, 2017 (File No. 005-89990).* Exhibit 7.04 Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Checkpoint Therapeutics, Inc. dated July 11, 2016 and effective as of March 17, 2015, incorporated by reference to Exhibit 10.2 to the Form 10-12G filed by the Issuer with the SEC on July 11, 2016 (File No. 000-55506).* Exhibit 7.05 First Amendment to the Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Checkpoint Therapeutics, Inc. dated October 5, 2017, incorporated by reference to Exhibit 10.2.1 to the Form 10-K filed by the Issuer with the SEC on March 18, 2019 (File No. 001-38128).* * Previously Filed. CUSIP No. 162828 206 Page 7 of 7 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: May 17, 2024 FORTRESS BIOTECH, INC. By: /s/ Lindsay A. Rosenwald, M.D. Name: Lindsay A. Rosenwald, M.D. Title: Chairman, President and Chief Executive Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR